BioCryst Pharmaceuticals, Inc.
BCRX
$8.80
$0.222.56%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -61.53% | 155.06% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -61.53% | 155.06% | |||
| Cost of Revenue | 35.88% | 3.33% | |||
| Gross Profit | -74.67% | 218.11% | |||
| SG&A Expenses | 3.33% | 10.23% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 14.58% | 7.74% | |||
| Operating Income | -101.44% | 801.28% | |||
| Income Before Tax | -390.63% | 1,944.66% | |||
| Income Tax Expenses | -53.78% | 382.44% | |||
| Earnings from Continuing Operations | -393.60% | 1,805.92% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -393.60% | 1,805.92% | |||
| EBIT | -101.44% | 801.28% | |||
| EBITDA | -101.04% | 747.63% | |||
| EPS Basic | -355.69% | 1,797.88% | |||
| Normalized Basic EPS | -107.69% | 1,650.68% | |||
| EPS Diluted | -364.51% | 1,777.67% | |||
| Normalized Diluted EPS | -107.99% | 1,660.05% | |||
| Average Basic Shares Outstanding | 14.83% | 0.38% | |||
| Average Diluted Shares Outstanding | 10.49% | -0.28% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||